Acquisition combines Aldevron's leadership in GMP manufacturing with Nature Tech's portfolio of proprietary technologies.

Aldevron has acquired Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include Nanoplasmid^TM, a proprietary vector construct that improves the safety and performance of plasmids and biologics. Aldevron and NTC have complementary service offerings and pairing Aldevron's world-class manufacturing capabilities with NTC's innovative solutions will further support our clients and the patients they serve.

For more information about Nature Technology Corporation's full suite of offerings, visit www.natx.com

To get started now, complete the form, and a client relations representative will be in contact very soon.

Aldevron is now offering its pALD-HELP, an off-the-shelf product supporting AAV viral vector manufacturing, in its proprietary GMP-Source® (GMP-S) quality level. The plasmid is royalty-free for all applications in support of pre-clinical activities through clinical development.

The addition of this widely used plasmid expands Aldevron’s suite of ready-to-use and royalty-free constructs in support of making AAV via triple transfection, including its rep/cap plasmids 2, 5 and 6. The pALD-AAV6 plasmid is also available at the GMP-Source quality level.

“We launched this Ad helper plasmid in Research Grade as an inventory product earlier this fall and it was very well received,” said Michelle Berg, President, GMP Nucleic Acids for Aldevron. “Offering pALD-HELP in our GMP-Source quality level is another way we can support our clients in their efforts to get potential therapies to their patients sooner. Aldevron continuously looks for ways to improve our service to clients and expanding our portfolio of standardized products across quality levels ensures they have the quality products they need, when they need them.”

Aldevron has more than 23 years of experience manufacturing high-quality custom products that are used by companies around the world, along with a catalog of products that provide a consistent, reliable option to help clients meet deadlines. In addition to the AAV construct suite, Aldevron’s inventory product lines also include lentivirus plasmids, IVT enzymes, and a variety of CRISPR nucleases.

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, and Aldevron, the leading provider of high-quality plasmid DNA, mRNA and recombinant proteins necessary for vaccines, gene and cell therapy, gene editing and diagnostic applications, announced today that Aldevron will support the development of ARU-1801, Aruvant’s one-time investigational gene therapy for sickle cell disease (SCD), and ARU-2801, a one-time investigational gene therapy for hypophosphatasia (HPP). Aldevron will provide good manufacturing practice (GMP)-grade plasmid for Aruvant’s upcoming ARU-1801 pivotal trial.

Moderna, Inc. (Nasdaq:MRNA), and Aldevron have announced their expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in Moderna’s clinical development pipeline. Specifically, Aldevron will supply plasmid DNA to serve as the genetic template for generating the COVID-19 mRNA vaccine and other investigational programs in Moderna’s pipeline.

Aldevron hosted its first Breakthrough Symposium (BTS) in Fall 2018 with an exciting lineup of industry leaders presenting their research and how it affects the present, and the future, of finding solutions to the world’s biggest health challenges.

Gene and cell therapy developers are contending with the implications of the evolving regulatory environment while trying to progress programs as quickly as possible to address unmet needs and secure first-mover advantage in competitive indications. Regulators are facilitating efforts to truncate development timelines through a series of designations that can expedite programs while also making efforts to implement standardization.

Aldevron is excited to share an update on our partner's progress regarding their AAVCOVID vaccine program. Mass Eye and Ear's novel gene-based vaccine strategy utilizes an adeno-associated virus (AAV) vector.

Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through clinical development and commercial production.